Sharma et al. and Heidarpour et al. indicated that therapy with first-generation somatostatin analogs (SSA—octreotide and lanreotide) through the control of excess GH and IGF-I and direct actions of SSA (somatostatin receptor types 1, 2, 4 and 5) on the heart and vessels, improved cardiovascular parameters (blood pressure, heart rate, systolic and diastolic function, exercise tolerance, left ventricular mass, QT interval duration, and arrhythmia rate) in patients who have not achieved complete biochemical control of the disease [11,77]. The gene discussed is SSTR1; the disease is Arrhythmia.